Results 261 to 270 of about 35,569 (305)

Glucagon-Like Peptide-1 Receptor Agonists

Surgical Clinics of North America
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...
Heather P. Whitley, Jennifer M. Trujillo
  +6 more sources

Association between glucagon‐like peptide‐1 receptor agonist use and peri‐operative pulmonary aspiration: a systematic review and meta‐analysis

Anaesthesia
INTRODUCTION: Glucagon-like peptide-1 receptor agonists are known to delay gastric emptying; however, the association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration risk is not known.
Priya Sumithran, Tim Spelman, Cade Shadbolt   +2 more
exaly   +2 more sources

Overview of Glucagon-like Peptide-1 Receptor Agonists

Home Healthcare Now, 2015
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman, Joan S, Grant, Lucinda J, Graven   +2 more
openaire   +2 more sources

Glucagon-like Peptide-1 Receptor Agonists

2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
Ja Young Jeon, Hae Jin Kim
openaire   +1 more source

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.
Sadiya S, Khan, Chiadi E, Ndumele, Dhruv S, Kazi   +2 more
openaire   +2 more sources

Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry

Journal of Clinical Psychopharmacology
The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. Finally, the pharmacological treatment of obesity seems to have a breakthrough after decades of setbacks, with previous weight ...
Himmerich, Hubertus, McElroy, Susan L
openaire   +3 more sources

Obesity and Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Francesca, Celletti, Francesco, Branca, Jeremy, Farrar   +2 more
openaire   +2 more sources

Cardioprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists

Kardiologiia, 2014
In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications ...
A S, Ametov, L L, Kamynina, Z G, Akhmedova   +2 more
openaire   +2 more sources

Glucagon-like peptide-1 receptor agonists and the eye

Current Opinion in Ophthalmology
Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown.
David L, Zhang, Avni P, Finn
openaire   +2 more sources

Renal protection with glucagon-like peptide-1 receptor agonists

Current Opinion in Pharmacology, 2020
There is an unmet need for renoprotective drugs for more pronounced reduction of albuminuria beyond that provided by renin-angiotensin system (RAS) blockers and for effective slowdown of eGFR decline independent of albuminuria. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have proven effective in reducing prespecified secondary composite ...
Vitale M., Haxhi J., Cirrito T., Pugliese G.   +3 more
openaire   +2 more sources